Literature DB >> 25319225

[Therapy-induced tumor regression and regression grading in lung cancer].

K Junker1.   

Abstract

After neoadjuvant therapy of non-small cell lung cancer, the extent of therapy-induced tumor regression in corresponding resection specimens of primary tumors and lymph nodes represents an independent prognostic factor. In the former tumor area, different sized target-like foci with central necrosis, adjoining narrow foam cell rim, peripheral vascular granulation tissue and transition into a marked scarry fibrosis can be found after neoadjuvant therapy. Morphological changes indicating therapy-induced tumor regression can be graded according to the Bochum regression grading system. Therapy-induced cytomorphological changes do not allow reliable conclusions on the success of the applied neoadjuvant therapy and should not form the basis of cytopathological grading.

Entities:  

Mesh:

Year:  2014        PMID: 25319225     DOI: 10.1007/s00292-014-1919-x

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  24 in total

1.  [Changes in differentiation of small cell lung cancer after chemotherapy].

Authors:  K Langner; K M Müller; K Junker
Journal:  Pathologe       Date:  2000-09       Impact factor: 1.011

2.  Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial.

Authors:  W Eberhardt; H Wilke; G Stamatis; M Stuschke; A Harstrick; H Menker; B Krause; M R Müeller; M Stahl; M Flasshove; V Budach; D Greschuchna; N Konietzko; H Sack; S Seeber
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

3.  Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer.

Authors:  Shin-Ichi Takeda; Hajime Maeda; Tatsuya Okada; Toshihiko Yamaguchi; Masaru Nakagawa; Soichiro Yokota; Noriyoshi Sawabata; Mitsunori Ohta
Journal:  Eur J Cardiothorac Surg       Date:  2006-05-26       Impact factor: 4.191

4.  [Neoadjuvant combined therapy in stage IIIA if non-small-cell bronchial cancer].

Authors:  M Thomas; C Rübe; M Semik; K Junker; M von Eiff
Journal:  Dtsch Med Wochenschr       Date:  1997-08-15       Impact factor: 0.628

5.  Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.

Authors:  N C Choi; R W Carey; W Daly; D Mathisen; J Wain; C Wright; T Lynch; M Grossbard; H Grillo
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

6.  Trimodality therapy in stage III non-small cell lung cancer: prediction of recurrence by assessment of p185neu.

Authors:  M Thomas; C Rübe; M Semik; M von Eiff; F Klinke; H N Macha; L Freitag; H H Scheld; N Willich; W E Berdel; K Junker
Journal:  Eur Respir J       Date:  1999-02       Impact factor: 16.671

7.  [Neoadjuvant therapy in non-small cell lung cancer. Prognostic impact of "mediastinal downstaging"].

Authors:  K Langner; M Thomas; F Klinke; U Bosse; A Heinecke; K-M Müller; K Junker
Journal:  Chirurg       Date:  2003-01       Impact factor: 0.955

8.  [Therapy-induced morphological changes in lung cancer].

Authors:  K Junker
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

9.  Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.

Authors:  Hale B Caglar; Elizabeth H Baldini; Megan Othus; Michael S Rabin; Raphael Bueno; David J Sugarbaker; Steven J Mentzer; Pasi A Jänne; Bruce E Johnson; Aaron M Allen
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

10.  A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor.

Authors:  Yuki Yamane; Genichiro Ishii; Koichi Goto; Motohiro Kojima; Masayuki Nakao; Yoshihisa Shimada; Yutaka Nishiwaki; Kanji Nagai; Hirotsugu Kohrogi; Atsushi Ochiai
Journal:  J Thorac Oncol       Date:  2010-01       Impact factor: 15.609

View more
  3 in total

1.  [Pathological-anatomical diagnosis according to the German lung cancer guideline 2018].

Authors:  K Junker; R Büttner; T Langer; D Ukena
Journal:  Pathologe       Date:  2018-11       Impact factor: 1.011

2.  Patient-derived tumor xenografts of lung squamous cell carcinoma alter long non-coding RNA profile but not responsiveness to cisplatin.

Authors:  Dapeng Lu; Peng Luo; Ju Zhang; Yuanyuan Ye; Qi Wang; Ming Li; Hangcheng Zhou; Mingran Xie; Baolong Wang
Journal:  Oncol Lett       Date:  2018-03-30       Impact factor: 2.967

3.  Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects.

Authors:  Slavisa Tubin; Helmut H Popper; Luka Brcic
Journal:  Radiat Oncol       Date:  2019-01-29       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.